A study, led by TB Alliance, has found 89 percent of participants on the trial have been cured of drug-resistant tuberculosis (TB) after six months of treatment and six months of post-treatment follow-up through a simplified, shortened all oral regimen.
The interim results from Nix-TB, an ongoing open label study carried out at three South African sites, analyse the outcomes of orally given bedaquiline, pretomanid and linezolid over six months for extensively drug-resistant (XDR-TB) or multidrug-resistant TB (MDR-TB).
Interim results of this all oral regimen for drug-resistant TB, which cover the first 75 patients who were enrolled for six months of treatment and an additional six months of follow-up, continue to be promising in terms of both efficacy and safety.
Of the 75 participants 68 percent had XDR-TB. Francesca Conradie, University of Witwatersrand, said: “This is an encouraging way forward for patients with complicated DR-TB.
“Previously reported rate of success has been surpassed by the first 75 patients who completed six months post-treatment follow up.”
Participants who complete treatment are being followed up with for 24 months after treatment ends.
The study will be completed towards the end of 2019.